Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ______________________________________________ FORM 10-Q ______________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to _________________ | --- ...

Exhibit 99.1 https://files.reportify.cc/medi Ginkgo Bioworks Reports Third Quarter 2024 Financial Results Ginkgo provides update on its restructuring process including an acceleration of site consolidation initiatives and continued progress on cost reductions Ginkgo signs new and expanded deals with Novo Nordisk and achieves a major research milestone with Merck BOSTON, Mass – November 12, 2024 – Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programmin ...

Ginkgo provides update on its restructuring process including an acceleration of site consolidation initiatives and continued progress on cost reductionsGinkgo signs new and expanded deals with Novo Nordisk and achieves a major research milestone with Merck  BOSTON, Nov. 12, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced its results for the third quarter ended September 30, 2024. The upda ...

BOSTON, Nov. 12, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the completion of the first milestone of a previously announced partnership with Merck, known as MSD outside of the United States and Canada, focused on improving biologic manufacturing. As part of this milestone completion, Ginkgo will receive a research milestone payment of $9 million in cash.The two companies will now move on to the second stage o ...

Presentation and Q&A session scheduled for post-market on Tuesday, November 12, 2024 BOSTON, Nov. 5, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business performance for the third quarter ended September 30, 2024, on Tuesday, November 12, 2024, beginning at 5:30 p.m. ET.The presentation details and webcast link will be ava ...

Ginkgo Bioworks Holdings, Inc. (DNA) ended the recent trading session at $7.63, demonstrating a -1.55% swing from the preceding day's closing price. This change lagged the S&P 500's 0.28% loss on the day. Elsewhere, the Dow lost 0.61%, while the tech-heavy Nasdaq lost 0.33%.The company's stock has dropped by 6.96% in the past month, falling short of the Medical sector's loss of 3.47% and the S&P 500's gain of 0.41%.Investors will be eagerly watching for the performance of Ginkgo Bioworks Holdings, Inc. in i ...

MENLO PARK, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced SPRQ, an improved sequencing chemistry for its Revio™ long-read sequencing system. The new chemistry will reduce Revio DNA input requirements by 4x to 500ng per sample, which enables more sample types such as saliva extracted with PacBio’s new Nanobind protocol and tumor samples to be sequenced with HiFi sequencing technology. It will also in ...

Dublin, Oct. 28, 2024 (GLOBE NEWSWIRE) -- The "DNA & RNA Banking Services Market Size, Share and Trends Analysis Report by Service, Specimen (Blood, Buccal Swabs & Hair Follicles, Others), Application, End-use 2024-2030" report has been added to ResearchAndMarkets.com's offering. The global DNA & RNA banking services market size is expected to reach USD 10.92 billion by 2030, registering a CAGR of 5.5% from 2024 to 2030. Biospecimens such as DNA and RNA are critical for biomarker discovery, thereby providin ...

NEW HAVEN, Conn., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Modifi Biosciences, Inc. (“Modifi Biosciences”), a leader in the development of direct DNA modification enabled cancer therapeutics, today announced that the company has been acquired by Merck, known as MSD outside of the United States and Canada. “In founding Modifi Biosciences, we sought to radically change the oncology treatment paradigm for cancer patients with glioblastoma and other tumors,” said Ranjit S. Bindra, MD, PhD, Modifi Biosciences Co-founde ...

Dublin, Oct. 15, 2024 (GLOBE NEWSWIRE) -- The "Pet DNA Testing Market Size, Share and Trends Analysis 2024-2030" report has been added to ResearchAndMarkets.com's offering. The global pet DNA testing market is expected to reach USD 676.64 million by 2030, registering to grow at a CAGR of 9.45% from 2024 to 2030. The key factors driving the industry growth include a rise in consumer genomics, high pet expenditure & pet humanization, increased awareness & sale of pet DNA testing products, and an increase in t ...